Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin Ying Zhang; Yoshiyasu Fukusumi; Mutsumi Kayaba; Takashi Nakamura; Ryusuke Sakamoto; Naoki Ashizawa; Hiroshi Kawachi;

Hiperuricemia en pacientes con enfermedad renal crónica: ¿cuándo y con qué tratar? Marian Goicoechea; Rodrigo García-Marina;

Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials Paulo Roberto Bignardi; Danielle Harumi Ido; Felipe Augusto Lopes Garcia; Lucas Mendes Braga; Vinicius Daher Alvares Delfino;